These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1687612)

  • 21. [Attention deficit hyperactivity disorder in children].
    Bervoets L
    J Pharm Belg; 2002; 57(2):25-32. PubMed ID: 12053824
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychosocial treatments for attention-deficit/hyperactivity disorder in children.
    Barkley RA
    J Clin Psychiatry; 2002; 63 Suppl 12():36-43. PubMed ID: 12562060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
    Işeri E; Kiliç BG; Senol S; Karabacak NI
    Methods Find Exp Clin Pharmacol; 2007; 29(1):47-52. PubMed ID: 17344944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New options in the pharmacological management of attention-deficit/hyperactivity disorder.
    Olfson M
    Am J Manag Care; 2004 Jul; 10(4 Suppl):S117-24. PubMed ID: 15352538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
    Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N
    Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline.
    Pelham WE; Greenslade KE; Vodde-Hamilton M; Murphy DA; Greenstein JJ; Gnagy EM; Guthrie KJ; Hoover MD; Dahl RE
    Pediatrics; 1990 Aug; 86(2):226-37. PubMed ID: 2196522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug therapy in the treatment of minimal brain dysfunction.
    Saccar CL
    Am J Hosp Pharm; 1978 May; 35(5):544-52. PubMed ID: 26219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coming into focus. Pharmacologic treatment for ADHD.
    McDonnell MA; Moffett C
    Adv NPs PAs; 2010 Dec; 1(4):16-22; quiz 23. PubMed ID: 21319448
    [No Abstract]   [Full Text] [Related]  

  • 33. BPD and ADHD.
    Lombardo GT
    J Am Acad Child Adolesc Psychiatry; 1997 Jun; 36(6):719-20. PubMed ID: 9183120
    [No Abstract]   [Full Text] [Related]  

  • 34. Attention-deficit hyperactivity disorder and brain-derived neurotrophic factor: a speculative hypothesis.
    Tsai SJ
    Med Hypotheses; 2003 Jun; 60(6):849-51. PubMed ID: 12699711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder.
    Wilens TE; Spencer TJ; Biederman J
    J Atten Disord; 2002 Mar; 5(4):189-202. PubMed ID: 11967475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug therapy for adults with attention-deficit hyperactivity disorder.
    Wilens TE
    Drugs; 2003; 63(22):2395-411. PubMed ID: 14609347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats.
    Garland EJ
    J Psychopharmacol; 1998; 12(4):385-95. PubMed ID: 10065914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Is drug therapy of hyperactive children justified?].
    Janols LO; von Knorring AL
    Lakartidningen; 1991 Sep; 88(38):3057-8, 3061. PubMed ID: 1681156
    [No Abstract]   [Full Text] [Related]  

  • 39. The mechanism of action of drugs used to treat attention-deficit hyperactivity disorder: focus on catecholamine receptor pharmacology.
    Shenker A
    Adv Pediatr; 1992; 39():337-82. PubMed ID: 1359740
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.
    Markowitz JS; Patrick KS
    Clin Pharmacokinet; 2001; 40(10):753-72. PubMed ID: 11707061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.